Skip to main content
Premium Trial:

Request an Annual Quote

Caris Life Sciences Seeks FDA Approval for Exome, Transcriptome CDx Assays

NEW YORK ─ Caris Life Sciences on Tuesday announced the submission of two premarket approval (PMA) applications to the US Food and Drug Administration for its MI Exome CDx and MI Transcriptome CDx sequencing assays.

The assays include important companion diagnostic biomarkers with therapy claims and detect all classes of alterations including genomic signatures for microsatellite instability (MSI), tumor mutation burden (TMB), and loss of heterozygosity (LOH), Irving, Texas-based Caris said.

The companion diagnostic assays are designed to identify the molecular information required to personalize care, David Halbert, founder, chairman and CEO of Caris, said in a statement.

MI Exome CDx is a next-generation sequencing-based test that uses DNA isolated from formalin-fixed paraffin embedded (FFPE) tumor tissue specimens for the qualitative detection of genomic alterations. The assay can identify genetic variants, including single nucleotide variants, insertions, and deletions; copy number alterations; MSI; TMB; and LOH.

MI Transcriptome CDx is an NGS test that utilizes RNA isolated from FFPE tumor tissue specimens for the qualitative detection of genomic and transcriptomic alterations. The assay is a broad, multigene panel used to identify gene fusions; transcript variants; genetic variants, including single nucleotide variants, insertions, and deletions; and gene expression changes. MI Transcriptome CDx received FDA Breakthrough Device designation in 2019, Caris noted.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.